Therapeutic cancer vaccines: current status and moving forward

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• The U.S. Food and Drug Administration (FDA) approved the first therapeutic cancer vaccine, marking a significant advancement.
• Numerous cancer vaccine platforms targeting various tumor-associated antigens are under investigation in clinical trials.
• The tumor microenvironment and immunosuppressive factors can impede the efficacy of current cancer vaccines.

Purpose of the Study:

• To review the current landscape of cancer vaccine development and evaluation.
• To discuss strategies for overcoming immunosuppression in cancer vaccine therapy.
• To explore the role of patient selection, clinical trial endpoints, and biomarkers in advancing cancer vaccine research.

Main Methods:

• Review of preclinical and clinical studies evaluating cancer vaccine platforms.
• Analysis of combination strategies involving vaccines with immune checkpoint inhibitors, chemotherapy, targeted therapies, and radiation.
• Discussion of factors influencing clinical trial design and biomarker utility.

Main Results:

• Multiple cancer vaccine platforms are in advanced clinical trials (Phase II and III).
• Combination therapies are being investigated to counteract tumor-induced immunosuppression.
• The selection of appropriate patient populations and endpoints is crucial for vaccine efficacy studies.

Conclusions:

• Cancer vaccine development is rapidly progressing, with ongoing efforts to enhance therapeutic effectiveness.
• Overcoming the immunosuppressive tumor microenvironment is key to successful cancer vaccine strategies.
• Biomarkers and optimized clinical trial designs will be vital for the future of cancer vaccines.